Merck

Merck-backed VectorY Therapeutics raises $138M series A to push forward ALS program
Fierce Biotech
Tue, 11/14/23 - 09:28 am
VectorY Therapeutics
funding
ALS
Merck
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
Motley Fool
Sun, 11/12/23 - 09:30 pm
Merck
Bristol Myers Squibb
antibody-drug conjugate
Merck's Keytruda nabs FDA nod in biliary tract cancer, catching up with AstraZeneca's Imfinzi
Fierce Pharma
Wed, 11/1/23 - 10:10 pm
Merck
AstraZeneca
biliary tract cancer
Keytruda
Imfinzi
Daiichi-Sankyo ups revenue forecast thanks to massive Merck deal
Fierce Biotech
Tue, 10/31/23 - 09:30 pm
Daiichi Sankyo
Merck
antibody-drug conjugate
‘We knew it was there’: AbbVie CEO says company favored internal work over potential Daiichi deal
Fierce Biotech
Sun, 10/29/23 - 08:56 pm
AbbVie
Daiichi Sankyo
Merck
antibody-drug conjugate
Tricks and Treats as Biopharma’s Q3 Earnings Season Gets Underway
BioSpace
Sun, 10/29/23 - 08:53 pm
earnings
Bristol Myers Squibb
Takeda
Novartis
Sanofi
Merck
Merck quarterly profit tops expectations on COVID pill surprise
Yahoo/Reuters
Thu, 10/26/23 - 10:53 pm
Merck
earnings
COVID-19
Merck terminates Phase II trials for Alzheimer’s drug due to liver toxicity
Clinical Trials Arena
Thu, 10/26/23 - 11:53 am
Merck
clinical trials
MK-1942
liver toxicity
Alzheimer's disease
Merck discontinues some cancer drug development with China's Sichuan Kelun
Reuters
Tue, 10/24/23 - 10:00 am
Merck
Sichuan Kelun Pharmaceutical
cancer
oncology
Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO
BioSpace
Mon, 10/23/23 - 05:15 pm
ESMO
Merck
Bristol Myers Squibb
bladder cancer
PD-1 inhibitors
Keytruda
Padcev
Opdivo
Merck's early KRAS data suggest combination-friendly safety
Fierce Biotech
Mon, 10/23/23 - 10:30 am
Merck
ESMO
KRAS inhibitors
Amgen
Lumakras
ESMO: AstraZeneca proposes adding Lynparza to Imfinzi as endometrial cancer race heats up
Fierce Pharma
Mon, 10/23/23 - 09:07 am
ESMO
AstraZeneca
Merck
Lynparza
endometrial cancer
ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long shadow
Fierce Pharma
Sun, 10/22/23 - 06:06 pm
ESMO
Bristol Myers Squibb
Opdivo
bladder cancer
Padcev
Keytruda
Merck
ESMO: In PD-1 battle GSK waged on Merck, Jemperli appears to show survival edge over Keytruda in lung cancer
Fierce Pharma
Fri, 10/20/23 - 11:47 am
Merck
GSK
Keytruda
Jemperli
ESMO
nonsquamous non-small cell lung cancer
Merck pays $4B upfront for rights to 3 Daiichi ADCs in huge bet on post-Keytruda future
Fierce Biotech
Fri, 10/20/23 - 09:55 am
Merck
Daiichi Sankyo
AstraZeneca
antibody-drug conjugate
ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer
Fierce Pharma
Wed, 10/18/23 - 11:42 am
Seagen
Astellas
Merck
Padcev
Keytruda
bladder cancer
ESMO
Merck Pushes Keytruda into Perioperative NSCLC Setting with FDA Approval
BioSpace
Tue, 10/17/23 - 09:36 pm
Merck
Keytruda
non-small cell lung cancer
Merck's Keytruda hits overall survival goal in early lung cancer as FDA decision nears
Fierce Pharma
Tue, 10/10/23 - 10:18 am
Merck
Keytruda
non-small cell lung cancer
Eikon cuts staff 'to become more efficient,' letter from CEO Perlmutter reveals
Fierce Biotech
Sun, 10/8/23 - 02:44 pm
Eikon Therapeutics
Roger Perlmutter
Merck
layoffs
Merck eyes new bladder cancer space with positive Keytruda trial in muscle-invasive disease
Fierce Pharma
Thu, 10/5/23 - 09:03 pm
Merck
Keytruda
bladder cancer
muscle-invasive urothelial carcinoma

Pages